While the United States has made considerable progress fighting the HIV/AIDS crisis since its peak in the 1980s, headway has not been equal among racial/ethnic groups. Overall, HIV rates have declined in the U.S. and the number of new infections over the last five years has dropped among Black Americans and white Americans. However, Hispanic...
The NLAAD webinars are open to everyone. The sessions will include time for questions and answers and their recording will be posted in the NLAAD website. All webinars will provide interpretation into Spanish. Review the webinar listing below and register now to take part in these important conversations. Register by clicking on each image. ...
The NLAAD webinar series will kick off TODAY at 3PM ET with a discussion about what is needed to make PrEP into the hands of everyone who needs it. Review the webinar listing below and register now to take part in these important conversations. Webinars are open to everyone. The sessions will include time for...
AIDSVu has released PrEP use data and maps by race/ethnicity at the state-level for 2022, showing that while PrEP use has continued to increase on average by 56% each year since its approval in 2012, significant inequities remain in PrEP use among Black and Hispanic people and in the Southern region of the country. These...
Gay and bisexual Latino migrants in the United States, especially but not only those who are undocumented, are vulnerable to higher rates of sexual risk behaviours and HIV transmission, a recent study published in Social Science and Medicine found. The study identified homophobia and HIV related stigma in their residential communities, barriers to well-paid work,...
Credits: this summary of the impact of HIV among Hispanics/Latinos by gender, sexual orientation and age group has been prepared by Luis A. Mares, LMSW GENERAL Hispanic/Latino Americans in the United States have to deal with a variety of social determinants of health that put them in a precarious position when it comes to...
Tuesday October 4th, 3pm “A different PrEP Option: A Presentation for PrEP Professionals” Apretude is the first and only long acting injectable PrEP for reducing the risk of getting HIV. Join us to this presentation given by ViiV laboratories with information about this new important medical advance in the HIV field. [Registration link] Wednesday...
TITUSVILLE, N.J., February 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed adults (HIV-1 RNA less than 50 copies per...
October 15 is National Latinx AIDS Awareness Day (NLAAD). This year’s theme, “Ending HIV is at your fingertips,” focuses on the tools already available to address the HIV epidemic, like HIV testing, PrEP, condom use, HIV treatment, and U=U, as we are dealing with the COVID-19 pandemic. Historically, HIV has disproportionately impacted Hispanic/Latinx Americans, and a broad...
